Caplacizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Caplacizumab" in English language version.

refsWebsite

Global rank English rank

3fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

2doi.org

2^nd place

2nih.gov

4^th place

2semanticscholar.org

11^th place

8^th place

2web.archive.org

1^st place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1ama-assn.org

3,257^th place

3,398^th place

1who.int

195^th place

302^nd place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1medpagetoday.com

9,274^th place

5,856^th place

1drugs.com

399^th place

333^rd place

1cancer.gov

1,684^th place

1,350^th place

ama-assn.org

Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.

canada.ca

health-products.canada.ca

"Cablivi Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.

cancer.gov

NCT05468320. "Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)". Clinicaltrials.gov. NCI. Retrieved 4 August 2024.{{cite web}}: CS1 maint: numeric names: authors list (link)

clinicaltrials.gov

Clinical trial number NCT02553317 for "A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)" at ClinicalTrials.gov

doi.org

Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J (November 2020). "A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura". Expert Review of Hematology. 13 (11): 1153–1164. doi:10.1080/17474086.2020.1819230. PMID 32876503. S2CID 221468324.
Poullin P, Bornet C, Veyradier A, Coppo P (June 2019). "Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura". Drugs of Today. 55 (6). Barcelona, Spain: 367–376. doi:10.1358/dot.2019.55.6.2989843. PMID 31250841. S2CID 195761938.

drugs.com

FDA Professional Drug Information

europa.eu

ema.europa.eu

"Cablivi EPAR". European Medicines Agency (EMA). 30 April 2009. Retrieved 3 December 2024.
"Cablivi EPAR". European Medicines Agency (EMA). Retrieved 7 September 2020.

fda.gov

"FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder". U.S. Food and Drug Administration (FDA) (Press release). 6 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Cablivi". U.S. Food and Drug Administration (FDA). 11 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.
"New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Retrieved 15 September 2020.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Cablivi". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medicines.org.uk

"Cablivi 10 mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 22 June 2020. Retrieved 22 August 2020.

medpagetoday.com

Immune Drug Tackles Microvascular Thrombosis Disorder. February 2016

nih.gov

pubmed.ncbi.nlm.nih.gov

Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J (November 2020). "A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura". Expert Review of Hematology. 13 (11): 1153–1164. doi:10.1080/17474086.2020.1819230. PMID 32876503. S2CID 221468324.
Poullin P, Bornet C, Veyradier A, Coppo P (June 2019). "Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura". Drugs of Today. 55 (6). Barcelona, Spain: 367–376. doi:10.1358/dot.2019.55.6.2989843. PMID 31250841. S2CID 195761938.

semanticscholar.org

api.semanticscholar.org

Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J (November 2020). "A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura". Expert Review of Hematology. 13 (11): 1153–1164. doi:10.1080/17474086.2020.1819230. PMID 32876503. S2CID 221468324.
Poullin P, Bornet C, Veyradier A, Coppo P (June 2019). "Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura". Drugs of Today. 55 (6). Barcelona, Spain: 367–376. doi:10.1358/dot.2019.55.6.2989843. PMID 31250841. S2CID 195761938.

web.archive.org

"FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder". U.S. Food and Drug Administration (FDA) (Press release). 6 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Cablivi". U.S. Food and Drug Administration (FDA). 11 February 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.

who.int

World Health Organization (WHO) (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).